关键词：膀胱过动症；泌尿科；存储；紧迫感；尿失禁
摘 要：Overactive bladder (or overactive bladder syndrome) is a urological condition characterized by storage symptoms such as urgency, changes in the frequency of urination, nocturia, or incontinence. Although not a life-threatening condition, it is often debilitating and stigmatized. The pathophysiology of overactive bladder is not characterized completely. The symptoms can be lifelong or relapsing and remitting or it can be resolved. An overactive bladder can affect anyone irrespective of their gender. It is caused by the abnormal contraction of the detrusor muscles of the bladder. An overactive bladder can also be related to neurological diseases such as Parkinson's disease and multiple sclerosis.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Product Profiles

04.1.1 Enablex/Emselex

04.1.2 Gelnique

04.1.3 Oxytrol

04.1.4 Botox

04.1.5 Sanctura/Sanctura XR

04.1.6 Myrbetriq

04.1.7 Vesicare

04.1.8 Detrol/Detrol LA

04.1.9 Toviaz

05. Market Research Methodology

05.1 Market Research Process

05.2 Research Methodology

06. Introduction

07. Market Landscape

07.1 Market Overview

07.2 Market Size and Forecast

07.3 Five Forces Analysis

08. Market Segmentation by Molecule Type

08.1 Biologics

08.2 Small Molecules

09. Market Segmentation by Route of

Administration

09.1 Oral

09.2 Parenteral

09.3 Topical

10. Market Segmentation by Class of drugs

10.1 Antimuscarinic Agents

10.2 Beta-3 Adrenergic Receptor Agonists

11. Market Segmentation by Dosage Form

11.1 Solid

11.2 Liquid

11.3 Semisolid

11.4 Transdermal

12. Rate of Incidence and Prevalence

13. Geographical Segmentation

14. Buying Criteria

15. Market Growth Drivers

16. Drivers and their Impact

17. Market Challenges

18. Impact of Drivers and Challenges

19. Market Trends

20. Trends and their Impact

21. Vendor Landscape

21.1 Competitive Scenario

21.1.1 Key News

21.1.2 Mergers and Acquisitions

21.2 Market Share Analysis 2013

21.2.1 Actavis

21.2.2 Allergan

21.2.3 Astellas Pharma

21.2.4 Pfizer

21.3 Other and Future Prominent Vendors

22. Pipeline Portfolio

23. Key Vendor Analysis

23.1 Actavis plc

23.1.1 Key Facts

23.1.2 Business Description

23.1.3 Business Segmentation

23.1.4 Business Segmentation by Revenue 2012 and 2013

23.1.5 Sales by Geography

23.1.6 Business Strategy

23.1.7 Key Information

23.1.8 SWOT Analysis

23.2 Allergan

23.2.1 Key Facts

23.2.2 Business Description

23.2.3 Business Segmentation

23.2.4 Revenue by Business Segmentation

23.2.5 Revenue Comparison 2011-2013

23.2.6 Revenue by Geographical Segmentation

23.2.7 Business Strategy

23.2.8 Key Developments

23.2.9 SWOT Analysis

23.3 Astellas Pharma

23.3.1 Key Facts

23.3.2 Business Overview

23.3.3 Product Segmentation

23.3.4 Product Segmentation by Revenue 2012 and 2013

23.3.5 Geographical Segmentation by Revenue 2013

23.3.6 Business Strategy

23.3.7 Recent Developments

23.3.8 SWOT Analysis

23.4 Pfizer

23.4.1 Key Facts

23.4.2 Business Overview

23.4.3 Business Segmentation by Revenue 2013

23.4.4 Business Segmentation by Revenue 2012 and 2013

23.4.5 Geographical Segmentation by Revenue

23.4.6 Business Strategy

23.4.7 Key Developments

23.4.8 SWOT Analysis

24. Other Reports in this Series